RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adaptive Biotechnologies Stock

Adaptive Biotechnologies ROE 2025

Adaptive Biotechnologies ROE

-0.79

Ticker

ADPT

ISIN

US00650F1093

WKN

A2PLR5

In 2025, Adaptive Biotechnologies's return on equity (ROE) was -0.79, a 7.72% increase from the -0.73 ROE in the previous year.

Adaptive Biotechnologies Aktienanalyse

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies Corp is a biotechnology company specializing in the discovery and development of therapies for various diseases. It was founded in 2009 by brothers Chad and Harlan Robins in Seattle, USA. Adaptive Biotechnologies Corp is a leading provider of immune sequencing technology and analysis of T-cell and B-cell receptors. The company's business model is based on the development of therapies through the analysis of patient samples. The company's artificial intelligence and machine learning make immune systems visible to fight pathogens. By creating an accurate profile of patients' immune systems, the company enables the development of personalized therapies tailored to the individual needs and disease profiles of patients. The company is divided into several divisions, including oncology, immunology, and research and development of therapeutics. In the field of oncology, Adaptive Biotechnologies Corp focuses on the discovery of cancer therapies by identifying T-cell receptor characteristics of patients who have responded to cancer treatments. The team at Adaptive Biotechnologies Corp works with various pharmaceutical and biotech companies to advance the discovery of cancer therapeutics. In the field of immunology, the company has also focused on the identification of rare and severe immune disorders to enable more targeted diagnostics and treatment. Adaptive Biotechnologies Corp provides immune and other research instruments and sample processing systems for the study of antigen-antibody interactions. In addition, the company has also developed its own products, including the ImmunTraCkeR® test system, which analyzes the immune response of critically ill patients to improve ongoing therapies or enable early detection of new diseases. Other products include the immunoSEQ® assay kit and the clonoSEQ® assay kit, which are used for sequencing patients' immune systems. These test systems allow for the detection of minimal residual routes of T-cell or B-cell receptors in patients' blood, enabling better monitoring of cancer and the creation of personalized treatment plans. Adaptive Biotechnologies Corp is particularly highly regarded in the pharmaceutical and biotech industry for novel therapeutics and biologics, and has already collaborated with many reputable companies including Genentech, Roche, and Microsoft. The company's mission is to accelerate progress in medical research and the development of new therapies to help patients around the world. In recent times, the company has played a crucial role in testing point-of-care COVID rapid tests. For example, it is working with universities such as the University of Pennsylvania to explore ways in which the tests can be utilized. The company is also developing its own COVID-19 tests that have undergone clinical testing. Overall, Adaptive Biotechnologies Corp is a successful biotechnology company with a unique focus on personalized medicine and therapies tailored to specific patient immune profiles. With its innovative products and services, as well as partnerships with industry leaders, the company has revolutionized the bio-IT world and become one of the leading companies in the industry. Adaptive Biotechnologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Adaptive Biotechnologies's Return on Equity (ROE)

Adaptive Biotechnologies's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Adaptive Biotechnologies's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Adaptive Biotechnologies's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Adaptive Biotechnologies’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Adaptive Biotechnologies stock

What is the ROE (Return on Equity) of Adaptive Biotechnologies this year?

The ROE of Adaptive Biotechnologies this year is -0.79 undefined.

How has the Return on Equity (ROE) of Adaptive Biotechnologies developed compared to the previous year?

The ROE of Adaptive Biotechnologies has increased by 7.72% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Adaptive Biotechnologies?

A high ROE indicates that Adaptive Biotechnologies generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Adaptive Biotechnologies?

A low ROE can indicate that Adaptive Biotechnologies is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Adaptive Biotechnologies affect the company?

A change in ROE (Return on Equity) of Adaptive Biotechnologies can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Adaptive Biotechnologies?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Adaptive Biotechnologies?

Some factors that can influence Adaptive Biotechnologies's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Adaptive Biotechnologies pay?

Over the past 12 months, Adaptive Biotechnologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptive Biotechnologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptive Biotechnologies?

The current dividend yield of Adaptive Biotechnologies is .

When does Adaptive Biotechnologies pay dividends?

Adaptive Biotechnologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptive Biotechnologies?

Adaptive Biotechnologies paid dividends every year for the past 0 years.

What is the dividend of Adaptive Biotechnologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptive Biotechnologies located?

Adaptive Biotechnologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptive Biotechnologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptive Biotechnologies from 10/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2025.

When did Adaptive Biotechnologies pay the last dividend?

The last dividend was paid out on 10/4/2025.

What was the dividend of Adaptive Biotechnologies in the year 2024?

In the year 2024, Adaptive Biotechnologies distributed 0 USD as dividends.

In which currency does Adaptive Biotechnologies pay out the dividend?

The dividends of Adaptive Biotechnologies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Adaptive Biotechnologies

Our stock analysis for Adaptive Biotechnologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptive Biotechnologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.